FDA OKs Dova’s Doptelet for low blood platelets in ITP patients

The FDA approves Dova Pharmaceuticals’ (NASDAQ:DOVA) supplemental marketing application for DOPTELET (avatrombopag) to include treatment of thrombocytopenia (low blood platelets) in adult patients with chronic immune thrombocytopenia who have failed to sufficiently respond to previous therapy.

The agency approved the thrombopoietin receptor agonist in May 2018 for chronic liver disease patients with thrombocytopenia who are undergoing an invasive procedure (this indication was approved in Europe two days ago).

Shares are up 21% premarket.

https://seekingalpha.com/news/3474239-fda-oks-dovas-doptelet-low-blood-platelets-itp-patients-shares-21-percent-premarket